Navigation Links
Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions

ROCKVILLE, Md., Oct. 17 /PRNewswire/ -- Glycotex, Inc. today announced that it has finalized an agreement with U.K.-based Advanced Medical Solutions (AMS) to study the use of GLYC-101 with wound dressings manufactured by AMS.

Through this collaboration, Glycotex and AMS have agreed to an initial phase of testing of the use of GLYC-101 with AMS' wound dressings. Under the agreement, in the event that this first phase of testing gives rise to favorable results, or generates data that suggest further research may be warranted, Glycotex and AMS will have an opportunity to extend their collaboration for the purposes of continued research.

About GLYC-101

GLYC-101 is intended to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate currently under development is a topical gel to be applied directly on the wound surface. The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers and diabetic ulcers.

In May 2006, Glycotex completed a Phase II clinical trial of GLYC-101 in Australia, in which GLYC-101 produced a statistically significant rate of wound area reduction versus combined placebo and standard care in patients with chronic venous ulcers. The results provided proof-of concept and dose-ranging information for GLYC-101. In U.S. clinical trials, GLYC-101 is being assessed for safety and effectiveness on wound closure in patients undergoing carbon dioxide laser skin resurfacing.

About Advanced Medical Solutions

Advanced Medical Solutions is a leading company in the development and manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative and technologically advanced woundcare products.

In-house natural and synthetic polymer technology is used to provide advanced wound dressings based on the moist healing principle. AMS' resources ensure a unique position as a vertically integrated 'one stop shop' to provide all categories of moist wound healing products. AMS has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

The acquisition of 49.4 percent of Corpura BV in May 2008 strengthened AMS' position in hydrophilic polyurethane foam -- the largest and fastest growing segment of the advanced woundcare market.

AMS' technology in cyanoacrylate based tissue adhesives is used either for the closure of small cuts and trauma wounds through to large surgical incisions, or for protecting or sealing skin to prevent breakdown or infection.

AMS' products currently serve the majority of the key global markets sold either direct or through strategic partners or distributors.

Visit --

About Glycotex, Inc.

Glycotex, Inc. is a U.S. based development stage biopharmaceutical company focused on discovering and developing therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications. It has licensed from Novogen Limited certain patent rights and know-how to use and exploit its technology in a wide range of wound healing applications. Glycotex, Inc. is an 81 percent owned subsidiary of Novogen Limited. For more information, visit

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates, costs and delays in the development and/or FDA approval, or the failure of our products to obtain such approval, uncertainties in clinical trial results, our inability to maintain or enter into, and the risks resulting from, our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, competitive factors, our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business, our inability to operate our business without infringing the patents and proprietary rights of others, general economic conditions, the failure of any products to gain market acceptance, our inability to obtain any additional required financing, technological changes, government regulation, changes in industry practice and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

SOURCE Glycotex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HealthSouth Finalizes Acquisition of Rehabilitation Unit at Medical Center of Arlington
2. HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital
3. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
4. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
5. Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center
6. QUANTEL Finalizes the Acquisition of WaveLight Aesthetic GmbH
7. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
8. Gene Network Sciences Announces Drug Development Collaboration with Biogen Idec
9. Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria
10. Varian Medical Systems Signs Collaboration Agreement to Bring Advanced Radiotherapy Equipment to Indonesia
11. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
Post Your Comments:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: